Lupin Limited secures FDA approval for Loteprednol Etabonate Ophthalmic Gel, enhancing treatment options for postoperative ...

Lupin Limited announces the spin-off of its consumer healthcare division, LupinLife Consumer Healthcare Ltd., into a wholly ...

Chouhan suggests buying Lupin at the current market price with a stop loss at Rs 1,940 and target price of Rs 2,035.

The move is part of Lupin's broader strategy to create a specialised consumer healthcare entity, particularly aimed at ...

Mumbai: Global pharma major Lupin Limited, has announced the strategic carve-out of its consumer healthcare business, ...

Indian drugmaker Lupin Ltd. has announced that it spinned off its consumer healthcare business with effect from July 1. The newly formed wholly owned subsidiary will be called as LupinLife Consumer ...

Pharmaceutical major Lupin Limited has announced the strategic spin-off of its consumer healthcare business, LupinLife ...

This is eligible for 180 days of generic drug exclusivity. The company will manufacture the product at its facility situated ...

The product is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery.

Lupin has launched Prucalopride tablets in the US following USFDA approval. The bowel disorder treatment enters a $184 ...

Lupin launches independent consumer healthcare entity to focus on India's self-care market, led by Anil Kaushal.

Lupin Ltd AGM: Check out the latest updates, dates, and news about the Lupin Ltd AGM at IIFL Capital.